IL126970A0 - Stimulation of host defense mechanisms against tumors - Google Patents

Stimulation of host defense mechanisms against tumors

Info

Publication number
IL126970A0
IL126970A0 IL12697097A IL12697097A IL126970A0 IL 126970 A0 IL126970 A0 IL 126970A0 IL 12697097 A IL12697097 A IL 12697097A IL 12697097 A IL12697097 A IL 12697097A IL 126970 A0 IL126970 A0 IL 126970A0
Authority
IL
Israel
Prior art keywords
stimulation
host defense
defense mechanisms
against tumors
mechanisms against
Prior art date
Application number
IL12697097A
Other languages
English (en)
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of IL126970A0 publication Critical patent/IL126970A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
IL12697097A 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against tumors IL126970A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
PCT/IB1997/000594 WO1997041886A1 (en) 1996-05-09 1997-05-05 Stimulation of host defence mechanisms against tumors

Publications (1)

Publication Number Publication Date
IL126970A0 true IL126970A0 (en) 1999-09-22

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12697097A IL126970A0 (en) 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against tumors
IL12697297A IL126972A0 (en) 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against viral challenges

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12697297A IL126972A0 (en) 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against viral challenges

Country Status (17)

Country Link
EP (2) EP0956040B1 (enExample)
JP (2) JP3806446B2 (enExample)
KR (2) KR100399499B1 (enExample)
CN (1) CN1154508C (enExample)
AR (2) AR007058A1 (enExample)
AT (2) ATE316793T1 (enExample)
AU (3) AUPN976596A0 (enExample)
BR (2) BR9709223A (enExample)
CA (2) CA2253902A1 (enExample)
DE (2) DE69735204T2 (enExample)
ES (2) ES2260790T3 (enExample)
ID (2) ID16885A (enExample)
IL (2) IL126970A0 (enExample)
NZ (2) NZ332690A (enExample)
TW (1) TW528599B (enExample)
WO (2) WO1997041883A1 (enExample)
ZA (1) ZA973988B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
DE602005002673T2 (de) 2004-04-29 2008-07-24 F. Hoffmann-La Roche Ag Nukleotidsequenzvariation im Gen NS5A als Marker
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501236A (enExample) * 1980-08-22 1982-07-15
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
AU9139091A (en) * 1990-12-14 1992-07-08 Schering Corporation Oral administration of alpha interferon to treat lung malignancies
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
BR9709068A (pt) * 1996-05-09 2000-01-11 Pharma Pacific Pty Ltd Processo de tratamento.

Also Published As

Publication number Publication date
WO1997041886A1 (en) 1997-11-13
EP0898478A4 (en) 1999-05-26
JP2000504027A (ja) 2000-04-04
NZ332688A (en) 2000-07-28
JP3806446B2 (ja) 2006-08-09
DE69735204D1 (de) 2006-04-13
AU724190B2 (en) 2000-09-14
CA2253908A1 (en) 1997-11-13
DE69735201D1 (de) 2006-04-13
BR9709066A (pt) 2000-01-04
AU729514B2 (en) 2001-02-01
AR007058A1 (es) 1999-10-13
JP3806444B2 (ja) 2006-08-09
AR007059A1 (es) 1999-10-13
ZA973988B (en) 1998-11-09
EP0956040B1 (en) 2006-02-01
ES2260794T3 (es) 2006-11-01
KR20000010882A (ko) 2000-02-25
KR20000010880A (ko) 2000-02-25
KR100399501B1 (ko) 2003-12-18
TW528599B (en) 2003-04-21
ID16886A (id) 1997-11-20
CN1154508C (zh) 2004-06-23
AU2399297A (en) 1997-11-26
KR100399499B1 (ko) 2003-12-18
WO1997041883A1 (en) 1997-11-13
JP2000504026A (ja) 2000-04-04
AUPN976596A0 (en) 1996-05-30
IL126972A0 (en) 1999-09-22
ES2260790T3 (es) 2006-11-01
CN1218409A (zh) 1999-06-02
CA2253902A1 (en) 1997-11-13
ATE316791T1 (de) 2006-02-15
EP0898478A1 (en) 1999-03-03
ATE316793T1 (de) 2006-02-15
EP0898478B1 (en) 2006-02-01
EP0956040A1 (en) 1999-11-17
NZ332690A (en) 2000-07-28
DE69735201T2 (de) 2006-09-21
ID16885A (id) 1997-11-20
DE69735204T2 (de) 2006-09-21
EP0956040A4 (enExample) 1999-11-17
AU2710997A (en) 1997-11-26
BR9709223A (pt) 2000-12-12

Similar Documents

Publication Publication Date Title
EP0963207A4 (en) GENE THERAPY AGAINST TUMORS BY INTERLEUKIN 12
AU4230196A (en) Treatment of pancreatic tumors with peptide yy and analogs thereof
ZA955010B (en) Enhanced crosslinking of natural tissues
IL128115A0 (en) Electromagnetic cardiac biostimulation
EP0758196A4 (en) COMPOSITIONS AND METHODS FOR TUMOR TREATMENT
AP9901494A0 (en) Methods of preventing breast cancer
ZA954984B (en) Compositions and methods for the treatment of tumors
ZA973987B (en) Stimulation of host defence mechanisms against viral challenges
GB9509572D0 (en) Cancer therapy
EP0998293A4 (en) TREATMENTS FOR CYTOKIN-RELATED DISEASES
EP0898478A4 (en) STIMULATION OF THE OWN PROTECTION AGAINST TUMORS
GB9703633D0 (en) Cancer therapy
AU4068897A (en) Human induced tumor protein
AUPO395996A0 (en) Stimulation of host defence mechanisms
AU6579698A (en) Human tumor suppressor
IL125523A0 (en) Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
GB9601507D0 (en) Treatment of non-neuronal cancer using HSV mutant
GB9623365D0 (en) Non-neuronal cancer treatment
GB9624800D0 (en) Methods of preventing breast cancer
ZA949229B (en) Tumor necrosis factor-gamma
HU9602191D0 (en) Therapy of rheumatism
HK1027832A (en) Use of pea3 in tumor suppression
AUPO955497A0 (en) Treatment of cancer
GB9612388D0 (en) Stimulation of muscles
GB9624386D0 (en) Stimulation of muscles

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees